Philip Morris International Inc. reports developments across its cigarette business and expanding smoke-free portfolio, including IQOS heated tobacco products, ZYN nicotine pouches and e-vapor offerings. Company news commonly covers quarterly results, shipment and revenue trends, product authorizations, brand collaborations, and updates tied to adult-smoker alternatives.
Recurring announcements also address U.S. and international regulatory matters, including FDA modified-risk tobacco product authorizations for IQOS, as well as annual shareholder meetings, board elections, executive compensation votes, auditor ratification, shareholder proposals, and corporate responsibility initiatives.
Philip Morris International (PM) announced that its U.S. businesses donated $340,000 to four military relief societies supporting service members and families. The contributions bring total giving to these organizations to $1,220,000. Recipients are Air & Space Forces Aid Society, Army Emergency Relief, Coast Guard Mutual Assistance, and Navy-Marine Corps Relief Society.
Philip Morris International (PM) has published its inaugural Taskforce on Nature-related Financial Disclosures (TNFD) Report, detailing nature-related dependencies, impacts, risks, and opportunities across its global value chain.
The company describes itself as an early adopter of the TNFD recommendations and ties the work to its Value Plan 2030+, where nature is one of six strategic priorities alongside consumers, circularity, climate, workforce, and value-chain workers. The report follows PMI’s 2025 Climate Transition Plan aligned with TCFD and includes “Stories of Impact” on water stewardship, biodiversity, soil restoration, and product circularity. PMI notes recognition on Forbes’ 2026 Net Zero Leaders list, ranking fourth. The release also highlights that smoke-free products generated approximately 42% of second-quarter 2026 net revenues, are sold in over 105 markets, and were used by an estimated 43 million legal-age consumers as of December 31, 2025, supported by more than $16 billion invested since 2008 and multiple FDA marketing and modified-risk authorizations.
Philip Morris International (PM) has raised its regular quarterly dividend by 8.8% to $1.60 per share, equivalent to an annualized rate of $6.40 per share, payable on October 26, 2026 to shareholders of record and with an ex-dividend date of October 2, 2026.
PMI has increased its annual dividend every year since 2008, totaling a 248% rise and a 7.2% compound annual growth rate. The company reports that smoke-free products accounted for about 42% of its second-quarter 2026 net revenues and were used by over 43 million legal-age consumers as of December 31, 2025. Since 2008, PMI has invested over $16 billion in developing and commercializing smoke-free products, some of which have received FDA marketing and modified-risk authorizations.
Philip Morris International (PM) and WSJ Intelligence released The Cognition Index Research Report, based on a survey of more than 2,500 business professionals in the United States, United Kingdom, Italy, South Africa and Brazil, examining how human cognition fits into an AI-driven workplace.
Respondents ranked Moral Judgment and Ethics (42%) and Empathy and Trust Building (40%) as the most important human attributes that AI is least likely to replicate. About 62% said human intuition should outweigh AI in creative work, and 50% favored human judgment even in data-driven areas like market analysis. Only 25% strongly agreed their organization has an effective process to fact-check AI outputs, while 46% saw critical thinking as a skill that must be actively protected from over-reliance on automated summaries. The study also projects rising corporate value for creative empathy (+13 percentage points) and adaptability (+9 percentage points). Background details highlight PMI’s smoke-free portfolio, with smoke-free products representing about 42% of its second-quarter 2026 net revenues and more than 43 million estimated adult users by December 31, 2025.
Philip Morris International (PM) raised its 2026 full-year reported diluted EPS forecast range to $7.28–$7.43, reflecting currency impacts only.
Excluding a total 2026 adjustment of $1.07 per share, the new forecast for adjusted diluted EPS of $8.35–$8.50 implies projected growth of 10.7%–12.7% versus $7.54 in 2025. On a basis excluding a favorable currency impact of $0.24 per share (previously $0.15), adjusted diluted EPS growth is projected at 7.5%–9.5%. The company also updated its Q3 2026 adjusted diluted EPS forecast to $2.29–$2.34, now including an estimated $0.01 favorable currency impact (previously an unfavorable $0.08).
PMI’s smoke-free products represented about 42% of Q2 2026 net revenues and were used by an estimated 43 million legal-age consumers as of December 31, 2025. Group CEO Jacek Olczak is scheduled to address investors at the 2026 Barclays Global Consumer Conference.
Philip Morris International (PM) announced the U.S. national rollout of ZYN's new brand platform and campaign, “When It Clicks”, centered on the distinctive “ZYN click” sound and the feeling when effort, timing, and confidence align.
The campaign targets busy legal-age adult nicotine users who want to stay present without stepping away, and will run across point of sale, digital, out-of-home, and live cultural events. Following a soft launch, PMI U.S. plans full national scale in Q4 2026, including a debut to retail trade partners at the NACS Show in early October and subsequent consumer-facing activations in music, entertainment, sport, and art. ZYN will also offer limited-edition metal cases featuring original artwork in an American Art Series, extending the platform beyond traditional advertising.
Philip Morris International (NYSE: PM) will host a live webcast of a fireside chat with Group CEO Jacek Olczak at the 2026 Barclays Global Consumer Conference on Tuesday, September 8, 2026, at approximately 9:45 a.m. ET. The webcast will be accessible online and via PMI’s IR mobile app, with an archived replay available for six months.
PMI highlights that smoke-free products represented about 42% of its Q2 2026 total net revenues and were used by an estimated 43 million legal-age consumers as of December 31, 2025. Since 2008, PMI has invested over $16 billion in smoke-free product development and scientific assessment.
Philip Morris International (NYSE: PM) announced that its non-U.S. affiliates have entered into a contract manufacturing arrangement for combustible cigarettes with Philip Morris USA, an Altria (NYSE: MO) operating company. Initial shipments under this collaboration are expected to start in early 2027, subject to operational readiness and regulatory requirements, and PMI does not expect a material impact on its 2026 financials.
PMI emphasized it has not commercialized combustible cigarettes in the U.S. and has no plans to do so; both PMI and Altria will continue to manage their own commercialization, distribution and regulatory activities. PMI highlighted its smoke-free strategy: as of December 31, 2025, an estimated 43 million legal-age consumers used its smoke-free products in over 105 markets, which generated approximately 42% of PMI’s Q2 2026 total net revenues. Since 2008, PMI has invested over $16 billion in developing and commercializing smoke-free products and noted multiple FDA marketing and Modified Risk Tobacco Product authorizations for IQOS, ZYN and General snus.
Altria (NYSE: MO) announced that its subsidiary Philip Morris USA has entered into a contract manufacturing arrangement with non-U.S. affiliates of Philip Morris International (NYSE: PM). The arrangement is intended to enhance the efficiency of PM USA’s traditional tobacco operations and support Altria’s 2028 Enterprise Goals by improving operational capabilities, generating economic benefits to fund its Vision and building capabilities that may be transferable to international nicotine efforts. Altria does not expect a material impact on its 2026 financial results, and both Altria and PMI will continue to operate independently, each retaining responsibility for commercialization, distribution and regulatory activities.
Philip Morris International (NYSE: PM) announced that the U.S. FDA has issued Marketing Granted Orders to its U.S. affiliate Swedish Match USA for 11 ZYN ULTRA moist oral nicotine pouch products. The authorizations cover all 9mg variants and one 11mg variant of ZYN ULTRA, while additional 11mg variants remain under FDA scientific review.
According to Philip Morris International, the decision follows a pre‑market scientific assessment in which the FDA concluded that permitting marketing of these products is “appropriate for the protection of public health.” PMI notes that ZYN ULTRA is tobacco‑leaf free, has higher moisture content than flagship ZYN pouches, and targets legal‑age nicotine consumers. The company highlights that smoke‑free products represented approximately 42% of its Q2 2026 net revenues and that it has invested over $16 billion in smoke‑free innovation since 2008.